Clinical Trials
177Lu Lu-DOTA-TATE in patients newly diagnosed with Grade 1 and Grade 2 advanced GEP-NET
Disease Type: Gastrointestinal , Disease Type: Gastroenteropancreatic neuroendocrine tumors
A phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of [177Lu]Lu-DOTA-TATE in patients newly diagnosed with Grade 1 and Grade 2 (Ki-67 <10%) advanced GEP-NET with high disease burden (NETTER-3) Protocol No.: CAAA601A62301
Locations
Roanoke